Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of high-flow nasal oxygen on hypoxaemia during procedural sedation: a systematic review and meta-analysis.

Anaesthesia·2022

Same author

Effect of high-flow vs. low-flow nasal plus mouthguard oxygen therapy on hypoxaemia during sedation: a multicentre randomised controlled trial.

Anaesthesia·2021

Same author

Life expectancy inequalities in Wales before COVID-19: an exploration of current contributions by age and cause of death and changes between 2002 and 2018.

Public health·2021

Same author

Accelerating global vaccination coverage of frontline workers and populations at risk of severe COVID-19 complications.

Public health·2021

Same author

Airway Management Considerations for Upper Gastrointestinal Endoscopic Procedures in COVID-19 Era.

Digestive diseases and sciences·2020

Same author

Determination of the strong coupling constant <math> </math> in next-to-next-to-leading order QCD using H1 jet cross section measurements: H1 Collaboration.

The European physical journal. C, Particles and fields·2020

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Ototoxicity after intraperitoneal chemotherapy: a case report.

L Nieves¹, J Currie, J Hoffman

¹Department of Obstetrics and Gynecology, Brody School of Medicine of East Carolina University, Greenville, North Carolina, USA. lucybeth-nieves@hotmail.com

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society

|April 17, 2007

Summary

Intraperitoneal cisplatin can cause permanent hearing loss in ovarian cancer patients. This study highlights the ototoxicity risks associated with this treatment, emphasizing the need for physician awareness and established protocols.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Related Experiment Videos

Last Updated: Jul 15, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Area of Science:

Oncology
Otolaryngology

Background:

The National Cancer Institute recommends intraperitoneal (IP) therapy for optimally debulked epithelial ovarian cancer.
Established drug regimens and administration methods for IP therapy are lacking.
Physician awareness of potential toxicities associated with IP therapy is limited.

Observation:

A case of acute bilateral tinnitus and hearing loss (ototoxicity grade 3) occurred in a patient receiving IP cisplatin.
The patient had optimally debulked stage IIIC papillary serous ovarian carcinoma.
The toxicity manifested four days after the first cycle of IP cisplatin infusion (100 mg/m²).

Findings:

Cisplatin, when administered via the intraperitoneal route, can lead to significant ototoxicity.
High-frequency hearing loss is a potentially serious and permanent adverse effect of cisplatin therapy.
This case underscores the need for vigilance regarding cisplatin-induced ototoxicity in clinical practice.

Implications:

Further research is needed to establish clear drug regimens and administration guidelines for IP therapy in ovarian cancer.
Healthcare providers must be educated on the potential toxicities, including ototoxicity, associated with IP cisplatin.
Patient monitoring for hearing loss should be considered during and after IP cisplatin treatment.